HCA Healthcare (HCA) – Research Analysts’ Recent Ratings Changes

Share on StockTwits

A number of firms have modified their ratings and price targets on shares of HCA Healthcare (NYSE: HCA) recently:

  • 1/30/2019 – HCA Healthcare had its price target raised by analysts at Oppenheimer Holdings Inc. from $142.00 to $150.00. They now have an “outperform” rating on the stock.
  • 1/30/2019 – HCA Healthcare had its price target raised by analysts at Leerink Swann from $160.00 to $175.00. They now have an “outperform” rating on the stock.
  • 1/30/2019 – HCA Healthcare had its price target raised by analysts at SunTrust Banks, Inc. to $175.00. They now have a “buy” rating on the stock.
  • 1/14/2019 – HCA Healthcare is now covered by analysts at Stephens. They set an “overweight” rating and a $143.00 price target on the stock.
  • 1/3/2019 – HCA Healthcare is now covered by analysts at Deutsche Bank AG. They set a “buy” rating and a $140.00 price target on the stock.
  • 1/2/2019 – HCA Healthcare was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “HCA Healthcare’s shares have outperformed its industry’s gain in a year’s time.  Its top line has been growing over the last several quarters on higher admissions as well as improved payor and service mix. A number of acquisitions helped the company gain a strong foothold in the industry, fueling its inorganic growth. The company has also raised its guidance from its previous projections. A strong balance sheet and free cash flow are a couple of other positives for the company. However, its high operating expenses continue to weigh on the margins. The company is expected to witness a rise in costs due its constant growth-related investments. Its high leverage is another concern.”
  • 12/31/2018 – HCA Healthcare had its “buy” rating reaffirmed by analysts at Zacks Investment Research. They now have a $134.00 price target on the stock. According to Zacks, “HCA Healthcare’s shares have outperformed its industry’s gain in a year’s time.  Its top line has been growing over the last several quarters on higher admissions as well as improved payor and service mix. A number of acquisitions helped the company gain a strong foothold in the industry, fueling its inorganic growth. The company has also raised its guidance from its previous projections. A strong balance sheet and free cash flow are a couple of other positives for the company. However, its high operating expenses continue to weigh on the margins. The company is expected to witness a rise in costs due its constant growth-related investments, which in turn would not allow the debts to reduce, remaining a concern.”
  • 12/20/2018 – HCA Healthcare was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “HCA Healthcare’s shares have outperformed its industry’s gain in a year’s time.  Its top line has been growing over the last several quarters on higher admissions as well as improved payor and service mix. A number of acquisitions helped the company gain a strong foothold in the industry, fueling its inorganic growth. The company has also raised its guidance from its previous projections. A strong balance sheet and free cash flow are a couple of other positives for the company. However, its high operating expenses continue to weigh on the margins. The company is expected to witness a rise in costs due its constant growth-related investments, which in turn would not allow the debts to reduce, remaining a concern.”
  • 12/19/2018 – HCA Healthcare was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $140.00 price target on the stock. According to Zacks, “HCA Healthcare’s shares have outperformed its industry’s gain in a year’s time.  Its top line has been growing over the last several quarters on higher admissions as well as improved payor and service mix. A number of acquisitions helped the company gain a strong foothold in the industry, fueling its inorganic growth. The company has also raised its guidance from its previous projections. A strong balance sheet and free cash flow are a couple of other positives for the company. However, its high operating expenses continue to weigh on the margins. The company is expected to witness a rise in costs due its constant growth-related investments, which in turn would not allow the debts to reduce, remaining a concern.”
  • 12/13/2018 – HCA Healthcare was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $150.00 price target on the stock. According to Zacks, “HCA Healthcare’s shares have outperformed its industry’s gain in a year’s time.  Its top line has been growing over the last several quarters on higher admissions as well as improved payor and service mix. A number of acquisitions helped the company gain a strong foothold in the industry, fueling its inorganic growth. The company has also raised its guidance from its previous projections. A strong balance sheet and free cash flow are a couple of other positives for the company. However, its high operating expenses continue to weigh on the margins. The company is expected to witness a rise in costs due its constant growth-related investments, which in turn would not allow the debts to reduce, remaining a concern.”
  • 12/11/2018 – HCA Healthcare was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “HCA Healthcare’s shares have outperformed its industry’s gain in a year’s time.  Its top line has been growing over the last several quarters on higher admissions as well as improved payor and service mix. A number of acquisitions helped the company gain a strong foothold in the industry, fueling its inorganic growth. The company has also raised its guidance from its previous projections. A strong balance sheet and free cash flow are a couple of other positives for the company. However, its high operating expenses continue to weigh on the margins. The company is expected to witness a rise in costs due its constant growth-related investments, which in turn would not allow the debts to reduce, remaining a concern.”

HCA Healthcare stock opened at $139.71 on Monday. HCA Healthcare Inc has a one year low of $93.03 and a one year high of $147.42. The company has a market cap of $48.08 billion, a P/E ratio of 14.30, a P/E/G ratio of 1.16 and a beta of 0.80.

HCA Healthcare (NYSE:HCA) last posted its quarterly earnings data on Tuesday, January 29th. The company reported $2.99 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.59 by $0.40. HCA Healthcare had a negative return on equity of 91.25% and a net margin of 8.11%. The company had revenue of $12.27 billion for the quarter, compared to the consensus estimate of $12.10 billion. During the same period in the previous year, the business earned $2.12 EPS. HCA Healthcare’s revenue for the quarter was up 6.2% compared to the same quarter last year. Analysts predict that HCA Healthcare Inc will post 10.02 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 29th. Shareholders of record on Friday, March 1st will be issued a dividend of $0.40 per share. The ex-dividend date of this dividend is Thursday, February 28th. This is an increase from HCA Healthcare’s previous quarterly dividend of $0.35. This represents a $1.60 annualized dividend and a yield of 1.15%. HCA Healthcare’s payout ratio is currently 14.33%.

In other HCA Healthcare news, insider Michael S. Cuffe sold 4,943 shares of HCA Healthcare stock in a transaction that occurred on Friday, November 9th. The stock was sold at an average price of $141.90, for a total transaction of $701,411.70. Following the sale, the insider now directly owns 33,240 shares in the company, valued at approximately $4,716,756. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Jane D. Englebright sold 5,081 shares of HCA Healthcare stock in a transaction that occurred on Friday, November 9th. The stock was sold at an average price of $141.90, for a total value of $720,993.90. Following the sale, the senior vice president now owns 16,504 shares in the company, valued at $2,341,917.60. The disclosure for this sale can be found here. Insiders have sold a total of 13,280 shares of company stock worth $1,845,721 over the last 90 days. 2.80% of the stock is owned by company insiders.

A number of hedge funds have recently bought and sold shares of the business. Quadrant Capital Group LLC increased its holdings in shares of HCA Healthcare by 11.2% in the 4th quarter. Quadrant Capital Group LLC now owns 847 shares of the company’s stock valued at $93,000 after acquiring an additional 85 shares during the last quarter. Advisor Partners LLC increased its holdings in shares of HCA Healthcare by 2.3% in the 4th quarter. Advisor Partners LLC now owns 5,079 shares of the company’s stock valued at $632,000 after acquiring an additional 113 shares during the last quarter. First Manhattan Co. increased its holdings in shares of HCA Healthcare by 21.1% in the 4th quarter. First Manhattan Co. now owns 1,090 shares of the company’s stock valued at $135,000 after acquiring an additional 190 shares during the last quarter. Norway Savings Bank increased its holdings in shares of HCA Healthcare by 4.9% in the 4th quarter. Norway Savings Bank now owns 4,310 shares of the company’s stock valued at $536,000 after acquiring an additional 200 shares during the last quarter. Finally, Benjamin F. Edwards & Company Inc. bought a new stake in shares of HCA Healthcare in the 4th quarter valued at approximately $25,000. Institutional investors own 69.98% of the company’s stock.

HCA Healthcare, Inc, through its subsidiaries, provides health care services. The company operates general, acute care hospitals that offer medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy services.

Featured Story: What is the balance sheet?

Receive News & Ratings for HCA Healthcare Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCA Healthcare Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply